The Association of the Cholesterol Efflux Capacity with the Paraoxonase 1 Q192R Genotype and the Paraoxonase Activity.

Arylesterase Cholesterol efflux capacity High-density lipoprotein Paraoxonase Polymorphism

Journal

Journal of atherosclerosis and thrombosis
ISSN: 1880-3873
Titre abrégé: J Atheroscler Thromb
Pays: Japan
ID NLM: 9506298

Informations de publication

Date de publication:
19 Mar 2024
Historique:
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 20 3 2024
Statut: aheadofprint

Résumé

Paraoxonase 1 (PON1) binds to high-density lipoprotein (HDL) and protects against atherosclerosis. However, the relationship between functional PON1 Q192R polymorphism, which is associated with the hydrolysis of paraoxon (POXase activity) and atherosclerotic cardiovascular disease (ASCVD), remains controversial. As the effect of PON1 Q192R polymorphism on the HDL function is unclear, we investigated the relationship between this polymorphism and the cholesterol efflux capacity (CEC), one of the biological functions of HDL, in association with the PON1 activity. The relationship between PON1 Q192R polymorphisms and CEC was investigated retrospectively in 150 subjects without ASCVD (50 with the PON1 Q/Q genotype, 50 with the Q/R genotype, and 50 with the R/R genotype) who participated in a health screening program. The POXase and arylesterase (AREase: hydrolysis of aromatic esters) activities were used as measures of the PON1 activity. The AREase activity was positively correlated with CEC independent of the HDL cholesterol levels. When stratified by the PON1 Q192R genotype, the POXase activity was also positively correlated with CEC independent of HDL cholesterol. PON1 Q192R R/R genotype carriers had a lower CEC than Q/Q or Q/R genotype carriers, despite having a higher POXase activity. Moreover, in a multiple regression analysis, the PON1 Q192R genotype was associated with the degree of CEC, independent of the HDL cholesterol and POXase activity. The PON1 Q192R R allele is associated with reduced CEC in Japanese people without ASCVD. Further studies on the impact of this association on the severity of atherosclerosis and ASCVD development are thus called for.

Identifiants

pubmed: 38508740
doi: 10.5551/jat.64711
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Kentaro Oniki (K)

Graduate School of Pharmaceutical Sciences, Kumamoto University.

Kayoko Ohura (K)

Graduate School of Pharmaceutical Sciences, Kumamoto University.
Headquarters for Admissions and Education, Kumamoto University.

Megumi Endo (M)

Graduate School of Pharmaceutical Sciences, Kumamoto University.

Daniel Akatwijuka (D)

Graduate School of Pharmaceutical Sciences, Kumamoto University.

Erika Matsumoto (E)

Graduate School of Pharmaceutical Sciences, Kumamoto University.

Teruya Nakamura (T)

Graduate School of Pharmaceutical Sciences, Kumamoto University.

Yasuhiro Ogata (Y)

Japanese Red Cross Kumamoto Health Care Center.

Minoru Yoshida (M)

Japanese Red Cross Kumamoto Health Care Center.

Mariko Harada-Shiba (M)

Cardiovascular Center, Osaka Medical and Pharmaceutical University.
Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.

Junji Saruwatari (J)

Graduate School of Pharmaceutical Sciences, Kumamoto University.

Masatsune Ogura (M)

Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.
Department of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University.

Teruko Imai (T)

Graduate School of Pharmaceutical Sciences, Kumamoto University.
Daiichi University of Pharmacy.

Classifications MeSH